Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt

La Rae Seemann, Sandeep Anand Padala, Azeem Mohammed, Nardos Belayneh

Research output: Contribution to journalArticle

Abstract

Tumor-induced osteomalacia is a rare hypophosphatemic disease caused by unregulated production of fibroblast growth factor 23 by a tumor, thereby inducing renal phosphate wasting and inhibiting appropriate increase of calcitriol production. Symptoms of tumor-induced osteomalacia, including muscle weakness, bone pain, and pathologic fractures, are nonspecific and warrant further workup. We report the case of a 50-year-old African American female with no known psychiatric illness who was admitted after a failed suicide attempt provoked by severe bone pain. She had been treated for fibromyalgia and hypophosphatemic rickets at other facilities with no improvement. The findings of profound renal phosphate wasting initiated further evaluation, which revealed an elevated fibroblast growth factor 23 level and a right proximal fibular mesenchymal tumor on octreotide scintigraphy. Magnetic resonance imaging confirmed the findings of a solid intramuscular tumor corresponding to the octreotide avid lesion. After wide excision of the tumor, serum phosphate and parathyroid hormone levels began to normalize. This case highlights the importance of extensively investigating the cause of bone pain, weakness, and fatigue in patients without a family history of hypophosphatemia or bone disorders. The aforementioned symptoms may precede recurrent pathological fractures, and a thorough workup ensures that a diagnosis of tumor is not delayed or overlooked, as tumor resection confers a favorable prognosis and dramatic increase in the quality of life for patients.

Original languageEnglish (US)
JournalJournal of Investigative Medicine High Impact Case Reports
Volume7
DOIs
StatePublished - Jan 1 2019

Fingerprint

suicide attempt
Fibroblasts
Suicide
pain
Tumors
diagnostic
Plasmas
Neoplasms
Spontaneous Fractures
Bone
Octreotide
Phosphates
genealogy
fatigue
Bone and Bones
Pain
quality of life
illness
Hypophosphatemic Rickets
Disease

Keywords

  • FGF23
  • fibroblast growth factor 23
  • hypophosphatemia
  • octreotide scintigraphy
  • osteomalacia
  • paraneoplastic syndromes
  • phosphaturic mesenchymal tumor
  • renal phosphate wasting
  • tumor-induced osteomalacia

ASJC Scopus subject areas

  • Epidemiology
  • Safety, Risk, Reliability and Quality
  • Safety Research

Cite this

Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator : Diagnostic Delay Leads to a Suicide Attempt. / Seemann, La Rae; Padala, Sandeep Anand; Mohammed, Azeem; Belayneh, Nardos.

In: Journal of Investigative Medicine High Impact Case Reports, Vol. 7, 01.01.2019.

Research output: Contribution to journalArticle

@article{4c2c955322cc4745a3f027a927fa1149,
title = "Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt",
abstract = "Tumor-induced osteomalacia is a rare hypophosphatemic disease caused by unregulated production of fibroblast growth factor 23 by a tumor, thereby inducing renal phosphate wasting and inhibiting appropriate increase of calcitriol production. Symptoms of tumor-induced osteomalacia, including muscle weakness, bone pain, and pathologic fractures, are nonspecific and warrant further workup. We report the case of a 50-year-old African American female with no known psychiatric illness who was admitted after a failed suicide attempt provoked by severe bone pain. She had been treated for fibromyalgia and hypophosphatemic rickets at other facilities with no improvement. The findings of profound renal phosphate wasting initiated further evaluation, which revealed an elevated fibroblast growth factor 23 level and a right proximal fibular mesenchymal tumor on octreotide scintigraphy. Magnetic resonance imaging confirmed the findings of a solid intramuscular tumor corresponding to the octreotide avid lesion. After wide excision of the tumor, serum phosphate and parathyroid hormone levels began to normalize. This case highlights the importance of extensively investigating the cause of bone pain, weakness, and fatigue in patients without a family history of hypophosphatemia or bone disorders. The aforementioned symptoms may precede recurrent pathological fractures, and a thorough workup ensures that a diagnosis of tumor is not delayed or overlooked, as tumor resection confers a favorable prognosis and dramatic increase in the quality of life for patients.",
keywords = "FGF23, fibroblast growth factor 23, hypophosphatemia, octreotide scintigraphy, osteomalacia, paraneoplastic syndromes, phosphaturic mesenchymal tumor, renal phosphate wasting, tumor-induced osteomalacia",
author = "Seemann, {La Rae} and Padala, {Sandeep Anand} and Azeem Mohammed and Nardos Belayneh",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/2324709619895162",
language = "English (US)",
volume = "7",
journal = "Journal of Investigative Medicine High Impact Case Reports",
issn = "2324-7096",
publisher = "Sage Publications",

}

TY - JOUR

T1 - Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator

T2 - Diagnostic Delay Leads to a Suicide Attempt

AU - Seemann, La Rae

AU - Padala, Sandeep Anand

AU - Mohammed, Azeem

AU - Belayneh, Nardos

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Tumor-induced osteomalacia is a rare hypophosphatemic disease caused by unregulated production of fibroblast growth factor 23 by a tumor, thereby inducing renal phosphate wasting and inhibiting appropriate increase of calcitriol production. Symptoms of tumor-induced osteomalacia, including muscle weakness, bone pain, and pathologic fractures, are nonspecific and warrant further workup. We report the case of a 50-year-old African American female with no known psychiatric illness who was admitted after a failed suicide attempt provoked by severe bone pain. She had been treated for fibromyalgia and hypophosphatemic rickets at other facilities with no improvement. The findings of profound renal phosphate wasting initiated further evaluation, which revealed an elevated fibroblast growth factor 23 level and a right proximal fibular mesenchymal tumor on octreotide scintigraphy. Magnetic resonance imaging confirmed the findings of a solid intramuscular tumor corresponding to the octreotide avid lesion. After wide excision of the tumor, serum phosphate and parathyroid hormone levels began to normalize. This case highlights the importance of extensively investigating the cause of bone pain, weakness, and fatigue in patients without a family history of hypophosphatemia or bone disorders. The aforementioned symptoms may precede recurrent pathological fractures, and a thorough workup ensures that a diagnosis of tumor is not delayed or overlooked, as tumor resection confers a favorable prognosis and dramatic increase in the quality of life for patients.

AB - Tumor-induced osteomalacia is a rare hypophosphatemic disease caused by unregulated production of fibroblast growth factor 23 by a tumor, thereby inducing renal phosphate wasting and inhibiting appropriate increase of calcitriol production. Symptoms of tumor-induced osteomalacia, including muscle weakness, bone pain, and pathologic fractures, are nonspecific and warrant further workup. We report the case of a 50-year-old African American female with no known psychiatric illness who was admitted after a failed suicide attempt provoked by severe bone pain. She had been treated for fibromyalgia and hypophosphatemic rickets at other facilities with no improvement. The findings of profound renal phosphate wasting initiated further evaluation, which revealed an elevated fibroblast growth factor 23 level and a right proximal fibular mesenchymal tumor on octreotide scintigraphy. Magnetic resonance imaging confirmed the findings of a solid intramuscular tumor corresponding to the octreotide avid lesion. After wide excision of the tumor, serum phosphate and parathyroid hormone levels began to normalize. This case highlights the importance of extensively investigating the cause of bone pain, weakness, and fatigue in patients without a family history of hypophosphatemia or bone disorders. The aforementioned symptoms may precede recurrent pathological fractures, and a thorough workup ensures that a diagnosis of tumor is not delayed or overlooked, as tumor resection confers a favorable prognosis and dramatic increase in the quality of life for patients.

KW - FGF23

KW - fibroblast growth factor 23

KW - hypophosphatemia

KW - octreotide scintigraphy

KW - osteomalacia

KW - paraneoplastic syndromes

KW - phosphaturic mesenchymal tumor

KW - renal phosphate wasting

KW - tumor-induced osteomalacia

UR - http://www.scopus.com/inward/record.url?scp=85077023606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077023606&partnerID=8YFLogxK

U2 - 10.1177/2324709619895162

DO - 10.1177/2324709619895162

M3 - Article

C2 - 31850815

AN - SCOPUS:85077023606

VL - 7

JO - Journal of Investigative Medicine High Impact Case Reports

JF - Journal of Investigative Medicine High Impact Case Reports

SN - 2324-7096

ER -